1Perou CM,Sorlie T. Molecular portraits of human breast tumours.Nature,2000,406:747-752.
2Swain,SM.Triple-negative breast cancer:metastatic risk and role of platinum agents. Paper presented at:44th Annual Meeting of the American Society of Clinical Oncology,May 30-June 3,2008,Chicago,IL.
3Jessica M,Janet R.Risk Factors for Triple-Negative BreastCancer in Women Under Age 45.Cancer Epidemiol Biomarkers Pre,2009,18(4):1157-1166.
4Arnes JB,Brunet JS,Stefansson I,et al.Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.Clin Cancer Res,2005,11:4003-4011.
5Sφrlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA,2001,98:10869-10874.
6Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin Cancer Res,2004,10:5367-5374.
7Livasy CA,Karaca G,Nanda R,et al.Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol,2006,19:264-271.
8Carey LA,Perou CM,Livasy CA,et al.Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study.JAMA,2006,295:2492-2502.
9Reinaldo D,Chacón and María V,Costanzo.Triple-negative breast cancer.Breast Cancer Research,2010,12(Suppl 2):S3.
10Sotiriou C,Phil D,Pusztaj J.Gene-expression signatures in breast cancer.N Engl J Med,2009,360:790-800.
7Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21[J]. Science, 1990, 250(4988):1684-1689.
8Miki Y, Swensen J, Shattuck ED, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 [J]. Science,1994,266(5182) :66-71.
9Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13[J]. Science, 1994,265(5181): 2088-2090.
10Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells[J]. Cell, 1997,88 (2) : 265- 275.
1Jemal A, Siegel R, Ward E, et al.Cancer statistics, 2008[J].CA Cancer J Clin, 2008,58(2) : 71-96.
2Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trialof weekly compared with every-3-wk paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 over expressers and random assignment to trastuzumab or not in HER-2 non over expressers: final results of cancer and leukemia group B protol 9840 [J]. J Clin Oncol, 2008,26(10) : 1642-1649.
3Nistic C, Bria E, Cuppone F, et al. Weekly epirubicin and paclitaxel with anulyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study [J]. Antieaneer Drugs, 2007,18 (6) : 687-692.
4llum JL, Dees EC, Chacko A, et al. Phase II trial of capecitabine and veekly paclitaxel as first-line therapy for metastatic breast cancer[J].J 21in Oneol, 2006,24 (27) : 4384-4390.
5Van Minckwitz G, Muller B. PARP is expssed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy [J].European Journal of Cancer Supplements, 2010,8 : 306.
6Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era [J].J Clin Oncol, 2005,23(9):2114-2116.
7Jemal A, Siegel R, Ward E, et al. Cancer statistics,2009[J]. CA Cancer J Clin,2009,59(4) 225 249.
8Anders CK,Zagar TM,Carey LA. The Management of' Early Stage and Metastatic Triple Negative Breast Cancer:A Review [J]. Hematol Oncol Clin North Am,2013,27(4) :737-749.
9Dent RA ,Lindeman GJ ,Clemons M ,et al. Phase I trial of the oral PARP inhibitor olapm~ib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer[J].Breast Cancer Res, 2013,15 (5) : R88.
10Gonzalez-Angulo AM,Timms KM,Liu S,et al. Incidence and out- come of BRCA mutations in unselected patients with triple recep- tor-negative breast cancer[J]. Clinical Cancer Research,2011,17 (5) : 1082-1089.
